Objective Capital


	back to homepage Objective Archives 2010: Feb \| Jan \| 2009: Dec \| Nov \| Oct \| Sep \| Aug \| ... Sofame Technologies (SDW.V) - recent news flow indicates the company continues to make progress Objective Comment, Dec 17, 2008 Read More \| Previous Reports NioGold Mining Corp (NOX.V) - assays continue to demonstrate potential Objective Comment, Dec 10, 2008 Read More \| Previous Reports Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns Objective Report, Dec 03, 2008 Bridge BioResearch plc is focused on innovative emerging drugs for the treatment of metabolic/lifestyle diseases. Its two lead candidates, currently advancing into clinical trials, are innovative drug concepts in the related fields of diabetes and obesity. With some glimmer of efficacy, and safety already in evidence, upcoming clinical validation could put the company on the road to lucrative upfront, milestone and royalty payments. Read More \| Previous Reports


	SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE! Objective, Independent, Experienced. Research you can trust!

	Yes! Subscribe me for the latest stock research from Objective.


	Email address

	My Password

	My information:
	First Name
	Family Name
	Title:

	Job title:
	Job function:
	Industry:
	I am a:
	To receive occasional printed reports complete your mailing address:
	Company Name (if any)
	Address


	City
	Postcode/Zip
	Country


	Please Read Objective's Terms of Use.

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839